Boca Raton, Florida – April 19, 2018
After 15 years of dedicated service to our Veterans, Robert G Frykberg, DPM, MPH has decided to retire from his role as Chief of Podiatry at the Phoenix VA Medical Center and as Director of the Phoenix VA Medical Center Podiatric Residency Program. He continues to hold the academic rank of Professor, University of Arizona College of Medicine-Phoenix and Adjunct Professor, Midwestern University Program in Podiatric Medicine. During his time at the VA, Dr Frykberg grew the Podiatry Program from approximately 14,000 patient visits per year to almost 25,000 outpatient encounters and over 400 operative procedures annually, with 12 full time and part time podiatrists. The associated Residency Program also grew from a two year program of six residents to a fully approved three year Podiatric Medicine and Surgery Program, training 12 residents each year and more than 50 students from around the nation. His research and writing interests have included all facets of lower extremity disorders, but are specifically focused on diabetic foot ulcers, infections, Charcot foot, and wound care. The author of nearly 100 peer-reviewed publications, he has also been the Editor of two textbooks: The High Risk Foot in Diabetes Mellitus (1991) and the Diabetic Charcot Foot (2010). His expertise in the Diabetic Foot translated into hundreds of speaking invitations nationally and internationally with numerous lecture engagements in China, India, Russia, South America, the UK, Vietnam, Japan, Indonesia, Italy, and all across Europe.
PRESENT CEO Alan Sherman, DPM stated, “Bob Frykberg, DPM, MPH is a legend in the podiatry world that has had as great an impact on the profession as any figure in history. He has generously shared his scholarly approach to research and teaching, ingrained in him during his training at Harvard, to a generation of residents and practicing clinicians around the world. There is no greater evangelist of the podiatrist’s central role in preventing and treating diabetic lower limb disease than this man. We are excited to be working even more closely with him now, in this next phase of his career.”